Applying Meta-Analytic-Predictive Priors with the R Bayesian Evidence Synthesis Tools

Use of historical data in clinical trial design and analysis has shown various advantages such as reduction of within-study placebo-treated number of subjects and increase of study power. The meta-analytic-predictive (MAP) approach accounts with a hierarchical model for between-trial heterogeneity in order to derive an informative prior from historical (often control) data. In this paper, we introduce the package RBesT (R Bayesian Evidence Synthesis Tools) which implements the MAP approach with normal (known sampling standard deviation), binomial and Poisson endpoints. The hierarchical MAP model is evaluated by MCMC. The numerical MCMC samples representing the MAP prior are approximated with parametric mixture densities which are obtained with the expectation maximization algorithm. The parametric mixture density representation facilitates easy communication of the MAP prior and enables via fast and accurate analytical procedures to evaluate properties of trial designs with informative MAP priors. The paper first introduces the framework of robust Bayesian evidence synthesis in this setting and then explains how RBesT facilitates the derivation and evaluation of an informative MAP prior from historical control data. In addition we describe how the meta-analytic framework relates to further applications including probability of success calculations.

[1]  Christian Röver,et al.  Bayesian Random-Effects Meta-Analysis Using the bayesmeta R Package , 2020 .

[2]  Douglas M. Bates,et al.  Fast and Elegant Numerical Linear Algebra Using the RcppEigen Package , 2013 .

[3]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[4]  Heinz Schmidli,et al.  Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials , 2017, Comput. Stat. Data Anal..

[5]  Heinz Schmidli,et al.  Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis , 2018, Statistics in medicine.

[6]  Heinz Schmidli,et al.  A practical guide to Bayesian group sequential designs , 2014, Pharmaceutical statistics.

[7]  Anthony O'Hagan,et al.  Kendall's Advanced Theory of Statistics: Vol. 2B, Bayesian Inference. , 1996 .

[8]  M. A. Best Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[9]  A. Zeileis,et al.  Extended Model Formulas in R : Multiple Parts and Multiple Responses , 2010 .

[10]  M. Kendall,et al.  Kendall's advanced theory of statistics , 1995 .

[11]  T. Hothorn,et al.  Multivariate Normal and t Distributions , 2016 .

[12]  Geoffrey J. McLachlan,et al.  Robust mixture modelling using the t distribution , 2000, Stat. Comput..

[13]  Steven Sun Cancer clinical trials – current and controversial issues in design and analysis , 2018, Journal of biopharmaceutical statistics.

[14]  Dirk Eddelbuettel,et al.  Seamless R and C++ Integration with Rcpp , 2013 .

[15]  Martyn Plummer,et al.  JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling , 2003 .

[16]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[17]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[18]  Michel Lang checkmate: Fast Argument Checks for Defensive R Programming , 2017, R J..

[19]  Tim Friede,et al.  Meta‐analysis of few small studies in orphan diseases , 2016, Research synthesis methods.

[20]  Anthony O'Hagan,et al.  Predictively consistent prior effective sample sizes , 2019, Biometrics.

[21]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[22]  Arne Leijon,et al.  Beta mixture models and the application to image classification , 2009, 2009 16th IEEE International Conference on Image Processing (ICIP).

[23]  Tim Friede,et al.  Random‐effects meta‐analysis of few studies involving rare events , 2018, Research synthesis methods.

[24]  P. Müller,et al.  Determining the Effective Sample Size of a Parametric Prior , 2008, Biometrics.

[25]  A. O'Hagan,et al.  Kendall's Advanced Theory of Statistics, Vol. 2b: Bayesian Inference. , 1996 .

[26]  Tim Friede,et al.  Using phase II data for the analysis of phase III studies: An application in rare diseases , 2016, Clinical trials.

[27]  Heinz Schmidli,et al.  Sample size re‐estimation incorporating prior information on a nuisance parameter , 2017, Pharmaceutical statistics.

[28]  D M Eddy,et al.  Practice policies: where do they come from? , 1990, JAMA.

[29]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[30]  Dirk Eddelbuettel,et al.  Rcpp: Seamless R and C++ Integration , 2011 .

[31]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[32]  Heinz Schmidli,et al.  The network meta-analytic-predictive approach to non-inferiority trials , 2013, Statistical methods in medical research.

[33]  Satrajit Roychoudhury,et al.  Designing and analysing clinical trials in mental health: an evidence synthesis approach , 2016, Evidence-Based Mental Health.

[34]  Satrajit Roychoudhury,et al.  Robust exchangeability designs for early phase clinical trials with multiple strata , 2016, Pharmaceutical statistics.

[35]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[36]  Nicky J Welton,et al.  Evidence Synthesis for Decision Making in Healthcare (Statistics in Practice) , 2012 .

[37]  L. Wasserman,et al.  A Reference Bayesian Test for Nested Hypotheses and its Relationship to the Schwarz Criterion , 1995 .

[38]  Jiqiang Guo,et al.  Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.

[39]  Frank Bretz,et al.  Beyond Randomized Clinical Trials: Use of External Controls , 2019, Clinical pharmacology and therapeutics.

[40]  Tim Friede,et al.  Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases , 2016, Biometrical journal. Biometrische Zeitschrift.

[41]  Jouni Kerman,et al.  Neutral noninformative and informative conjugate beta and gamma prior distributions , 2011 .

[42]  Nicky J Welton,et al.  Evidence Synthesis for Decision Making in Healthcare , 2012 .

[43]  Leonhard Held,et al.  Network meta‐analysis with integrated nested Laplace approximations , 2015, Biometrical journal. Biometrische Zeitschrift.

[44]  Anthony O'Hagan,et al.  Assurance in clinical trial design , 2005 .

[45]  Lisa V Hampson,et al.  Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods , 2018, Statistical methods in medical research.

[46]  A. Gelman Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) , 2004 .

[47]  Anthony O'Hagan,et al.  Bayesian heavy-tailed models and conflict resolution: A review , 2012 .

[48]  A. Genz,et al.  Computation of Multivariate Normal and t Probabilities , 2009 .

[49]  Heinz Schmidli,et al.  Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian‐frequentist approach , 2018, Biometrical journal. Biometrische Zeitschrift.

[50]  Désirée van der Heijde,et al.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[51]  Donald A. Berry,et al.  Meta-Analysis in Medicine and Health Policy , 2000 .

[52]  Gerta Rücker,et al.  Network Meta-Analysis using Frequentist Methods , 2015 .

[53]  Bradley P Carlin,et al.  Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation , 2017, Pharmaceutical statistics.

[54]  D. Spiegelhalter,et al.  Monitoring clinical trials: conditional or predictive power? , 1986, Controlled clinical trials.

[55]  Gerta Rücker,et al.  Network meta‐analysis, electrical networks and graph theory , 2012, Research synthesis methods.

[56]  Human Medicines Development and Evaluation Concept paper on extrapolation of efficacy and safety in medicine development , 2012 .

[57]  Tim Friede,et al.  Model averaging for robust extrapolation in evidence synthesis , 2018, Statistics in medicine.

[58]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[59]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[60]  Nicky J Welton,et al.  Network Meta-Analysis for Decision-Making , 2018 .

[61]  Aki Vehtari,et al.  Visualization in Bayesian workflow , 2017, Journal of the Royal Statistical Society: Series A (Statistics in Society).

[62]  B. Holzhauer Meta‐analysis of aggregate data on medical events , 2017, Statistics in medicine.

[63]  Heinz Schmidli,et al.  On the Use of Co-Data in Clinical Trials , 2016 .

[64]  Lifeng Lin,et al.  Performing Arm-Based Network Meta-Analysis in R with the pcnetmeta Package. , 2017, Journal of statistical software.

[65]  W. J. Hall,et al.  Approximating Priors by Mixtures of Natural Conjugate Priors , 1983 .

[66]  Dirk Eddelbuettel,et al.  Extending R with C++: A Brief Introduction to Rcpp , 2018, PeerJ Prepr..

[67]  Frank Bretz,et al.  Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint , 2007, Statistics in medicine.

[68]  D. Spiegelhalter,et al.  Summarizing historical information on controls in clinical trials , 2010, Clinical trials.

[69]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[70]  Guochen Song,et al.  Bayesian methods for the design and analysis of noninferiority trials , 2016, Journal of biopharmaceutical statistics.

[71]  Heinz Schmidli,et al.  Using historical control information for the design and analysis of clinical trials with overdispersed count data , 2013, Statistics in medicine.

[72]  Heinz Schmidli,et al.  Use of Historical Data , 2016, Bayesian Methods in Pharmaceutical Research.

[73]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[74]  Robert Hemmings,et al.  Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics. , 2019, British journal of clinical pharmacology.

[75]  R. Shanmugam Quantifying Prior Opinion in Length-Biased Linear Mean Natural Exponential Family , 1992 .

[76]  Satrajit Roychoudhury,et al.  Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance , 2018, Clinical trials.

[77]  M. West Approximating posterior distributions by mixtures , 1993 .